Clearside Biomedical (NASDAQ:CLSD) released its earnings results on Thursday. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.12), Fidelity Earnings reports.
Shares of CLSD traded down $0.14 during mid-day trading on Friday, reaching $1.84. The company had a trading volume of 707,532 shares, compared to its average volume of 703,408. Clearside Biomedical has a 1-year low of $1.83 and a 1-year high of $15.33. The company has a current ratio of 7.94, a quick ratio of 7.94 and a debt-to-equity ratio of 0.15. The company has a market cap of $70.13 million, a P/E ratio of -0.79 and a beta of -3.98.
Institutional investors and hedge funds have recently bought and sold shares of the company. Voya Investment Management LLC acquired a new stake in shares of Clearside Biomedical in the 2nd quarter valued at approximately $123,000. Highland Capital Management LLC acquired a new stake in Clearside Biomedical during the 2nd quarter worth approximately $128,000. Cubist Systematic Strategies LLC acquired a new stake in Clearside Biomedical during the 1st quarter worth approximately $132,000. Dynamic Technology Lab Private Ltd acquired a new stake in Clearside Biomedical during the 1st quarter worth approximately $152,000. Finally, Trustcore Financial Services LLC boosted its position in Clearside Biomedical by 280.3% during the 2nd quarter. Trustcore Financial Services LLC now owns 14,585 shares of the company’s stock worth $156,000 after buying an additional 10,750 shares during the period. Institutional investors own 62.23% of the company’s stock.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
See Also: Stock Split
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.